Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...
SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss DrugsSAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Medpage Today on MSN5d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback